STTR Phase II: Portable Single Cell Cytology and Predictive Analysis Platform for the Earl — NSF Award to ORALIVA, INC. (NC, $1,24
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to optimize an accurate and efficient early stage, point of care cancer diagnostic for commercialization and market entry. In 2020, the total cost of cancer care was nearly $210 billion dollars and current canc
| Award title | STTR Phase II: Portable Single Cell Cytology and Predictive Analysis Platform for the Earl |
|---|---|
| Award ID | 2524897 |
| Awardee | ORALIVA, INC. |
| City | DURHAM |
| State | NC |
| Amount obligated | $1,244,392 |
| Principal investigator | Nicolaos Christodoulides |
| Program | STTR Phase II |
| Start date | 08/15/2025 |
| Abstract | The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to optimize an accurate and efficient early stage, point of care cancer diagnostic for commercialization and market entry. In 2020, the total cost of cancer care was nearly $210 billion dollars and current cancer diagnostics only allow for diagnosis during late stage disease, resulting in a large economic burden to patients, families, and healthcare providers. Commercialization of the co |
| Source | NSF Awards |
$799/mo
Try NSFGrants →